person · Reporting owner

GRYSKA DAVID W

Disclosed activity across 8 companies

Tapewire entity: 19062
SEC CIK: 0001202335

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Celcuity Inc.CELC · Entity 3991	Director	October 01, 2026	October 05, 2026
Definium Therapeutics, Inc.DFTX · Entity 3884	Director	June 11, 2026	June 15, 2026
INCYTE CORPINCY · Entity 3182	Executive Vice President, CFO	July 16, 2018	July 18, 2018
PDL BIOPHARMA, INC.PDLI · Entity 143144	Director	December 30, 2020	December 31, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Celcuity Inc.

Report date October 01, 2026 · Filed October 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	893	Reported balance After 2026-10-01 transaction · row 1 1 source row Row 1 · 2026-10-01 · Grant · Acquired 893 · Balance 893 F1: Represents restricted stock units that will vest upon the earlier of (i) the 2027 annual meeting of stockholders of Celcuity Inc. or (ii) April 30, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that will vest upon the earlier of (i) the 2027 annual meeting of stockholders of Celcuity Inc. or (ii) April 30, 2027.

Definium Therapeutics, Inc.

Report date June 11, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	19,900	Reported balance After 2026-06-11 transaction · row 1 1 source row Row 1 · 2026-06-11 · Grant · Acquired 4,666 · Balance 19,900 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.11 · Expires 2036-06-10	Direct	19,188	Reported balance After 2026-06-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-11 · Grant · Acquired 19,188 · Balance 19,188 F2: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.

F2: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.

INCYTE CORP

Report date July 16, 2018 · Filed July 18, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,235	Reported balance After 2018-07-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2018-07-16 · Tax withholding · Disposed 455 · Balance 10,235 F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

PDL BIOPHARMA, INC.

Report date December 30, 2020 · Filed December 31, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	1,387	Reported balance After 2020-12-30 transaction · row 1 1 source row Row 1 · 2020-12-30 · Sale · Disposed 20,000 · Balance 1,387

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AERIE PHARMACEUTICALS INC

Report date November 21, 2022 · Filed November 21, 2022

Section 16 reporting ended · disclosed 2022-11-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-11-21 transaction · row 1 1 source row Row 1 · 2022-11-21 · Disposition to issuer · Disposed 11,495 · Balance 0 F1: Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes.
Common StockSEC Table I · non-derivative	IndirectBy the Gryska Family Trust	Reported balance After 2022-11-21 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-11-21 · Disposition to issuer · Disposed 1,996 · Balance 0 F1: Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.27 · Expires 2030-06-11	Direct	Reported balance After 2022-11-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-11-21 · Disposition to issuer · Disposed 7,800 · Balance 0 F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.11 · Expires 2032-06-09	Direct	Reported balance After 2022-11-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-11-21 · Disposition to issuer · Disposed 16,854 · Balance 0 F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes.

F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration.

Forte Biosciences, Inc.

Report date August 27, 2026 · Filed August 27, 2026

Section 16 reporting ended · disclosed 2026-08-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-08-27 transaction · row 1 1 source row Row 1 · 2026-08-27 · Other · Disposed 5,940 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $77.00 per share ("Merger Consideration"), net to the seller in cash, without interest, subject to any required withholding tax. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.50 · Expires 2033-01-10	Direct	Reported balance After 2026-08-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-08-27 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2033-09-19	Direct	Reported balance After 2026-08-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-08-27 · Disposition to issuer · Disposed 1,000 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.54 · Expires 2035-03-20	Direct	Reported balance After 2026-08-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-08-27 · Disposition to issuer · Disposed 31,000 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.
Stock Option (right to buy)]SEC Table II · derivative / convertible security · Conversion / exercise price $8.60 · Expires 2034-08-20	Direct	Reported balance After 2026-08-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-08-27 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-08-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-08-27 · Disposition to issuer · Disposed 18,353 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock. F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $77.00 per share ("Merger Consideration"), net to the seller in cash, without interest, subject to any required withholding tax. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.

F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.

F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.

F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger.

GW PHARMACEUTICALS PLC

Report date May 05, 2021 · Filed May 07, 2021

Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2021-05-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-05-05 · Disposition to issuer · Disposed 35,208 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. F2: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2021-05-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-05-05 · Disposition to issuer · Disposed 22,464 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. F2: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3: These stock options were granted with automatic vesting on exercisable date.

Filing footnotes · ownership attribution and instrument terms

F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.

F2: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.

F3: These stock options were granted with automatic vesting on exercisable date.

Seagen Inc.

Report date December 14, 2023 · Filed December 15, 2023

Section 16 reporting ended · disclosed 2023-12-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-12-14 transaction · row 1 1 source row Row 1 · 2023-12-14 · Disposition to issuer · Disposed 49,003 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.25 · Expires 2024-05-16	Direct	Reported balance After 2023-12-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-12-14 · Disposition to issuer · Disposed 8,750 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.94 · Expires 2025-05-15	Direct	Reported balance After 2023-12-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.82 · Expires 2026-05-20	Direct	Reported balance After 2023-12-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.60 · Expires 2027-05-19	Direct	Reported balance After 2023-12-14 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.77 · Expires 2028-05-18	Direct	Reported balance After 2023-12-14 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.38 · Expires 2029-05-20	Direct	Reported balance After 2023-12-14 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-12-14 · Disposition to issuer · Disposed 7,038 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $160.33 · Expires 2030-05-15	Direct	Reported balance After 2023-12-14 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-12-14 · Disposition to issuer · Disposed 3,171 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $147.50 · Expires 2031-05-14	Direct	Reported balance After 2023-12-14 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-12-14 · Disposition to issuer · Disposed 3,462 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.63 · Expires 2032-05-13	Direct	Reported balance After 2023-12-14 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-12-14 · Disposition to issuer · Disposed 3,676 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-12-14 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2023-12-14 · Disposition to issuer · Disposed 2,044 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").

F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 19, 2022 Filed Apr 21, 2022 18:37 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	1,516	$144.17	$218,561.72	Disclosure SEC source: 0001203311-22-000021 · edgardoc.xml · nonDerivative · entry 4 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $143.84 to $144.83. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
April 19, 2022 Filed Apr 21, 2022 18:37 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	1,516	$20.06	$30,410.96	Disclosure SEC source: 0001203311-22-000021 · edgardoc.xml · nonDerivative · entry 3 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,766 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
April 19, 2022 Filed Apr 21, 2022 18:37 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	1,794	$143.32	$257,116.08	Disclosure SEC source: 0001203311-22-000021 · edgardoc.xml · nonDerivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $142.84 to $143.82. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
April 19, 2022 Filed Apr 21, 2022 18:37 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	1,794	$20.06	$35,987.64	Disclosure SEC source: 0001203311-22-000021 · edgardoc.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
February 07, 2022 Filed Feb 9, 2022 18:58 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	2,371	$0.00 Strike: $20.06	$0.00	Disclosure SEC source: 0001203311-22-000013 · edgardoc.xml · derivative · entry 9 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 2,371 shares Expires 2022-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Options were fully vested on 5/17/13. Read SEC document
February 07, 2022 Filed Feb 9, 2022 18:58 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	1,029	$0.00 Strike: $20.06	$0.00	Disclosure SEC source: 0001203311-22-000013 · edgardoc.xml · derivative · entry 8 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,371 Underlying: Common Stock · 1,029 shares Expires 2022-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Options were fully vested on 5/17/13. Read SEC document
February 07, 2022 Filed Feb 9, 2022 18:58 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	1,100	$0.00 Strike: $20.06	$0.00	Disclosure SEC source: 0001203311-22-000013 · edgardoc.xml · derivative · entry 7 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,400 Underlying: Common Stock · 1,100 shares Expires 2022-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Options were fully vested on 5/17/13. Read SEC document
February 07, 2022 Filed Feb 9, 2022 18:58 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	2,371	$139.42	$330,564.82	Disclosure SEC source: 0001203311-22-000013 · edgardoc.xml · nonDerivative · entry 6 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $139.20 to $139.99. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
February 07, 2022 Filed Feb 9, 2022 18:58 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	2,371	$20.06	$47,562.26	Disclosure SEC source: 0001203311-22-000013 · edgardoc.xml · nonDerivative · entry 5 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
February 07, 2022 Filed Feb 9, 2022 18:58 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	1,029	$138.66	$142,681.14	Disclosure SEC source: 0001203311-22-000013 · edgardoc.xml · nonDerivative · entry 4 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $138.03 to $139.00. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
February 07, 2022 Filed Feb 9, 2022 18:58 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	1,029	$20.06	$20,641.74	Disclosure SEC source: 0001203311-22-000013 · edgardoc.xml · nonDerivative · entry 3 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
February 07, 2022 Filed Feb 9, 2022 18:58 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	1,100	$137.45	$151,195.00	Disclosure SEC source: 0001203311-22-000013 · edgardoc.xml · nonDerivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $137.03 to $137.98. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
February 07, 2022 Filed Feb 9, 2022 18:58 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	1,100	$20.06	$22,066.00	Disclosure SEC source: 0001203311-22-000013 · edgardoc.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
January 28, 2022 Filed Feb 1, 2022 18:42 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	214	$0.00 Strike: $20.06	$0.00	Disclosure SEC source: 0001203311-22-000008 · edgardoc.xml · derivative · entry 12 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 214 shares Expires 2022-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options were fully vested on 5/17/13. Read SEC document
January 28, 2022 Filed Feb 1, 2022 18:42 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	883	$0.00 Strike: $20.06	$0.00	Disclosure SEC source: 0001203311-22-000008 · edgardoc.xml · derivative · entry 11 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,714 Underlying: Common Stock · 883 shares Expires 2022-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options were fully vested on 5/17/13. Read SEC document
January 28, 2022 Filed Feb 1, 2022 18:42 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	2,553	$0.00 Strike: $20.06	$0.00	Disclosure SEC source: 0001203311-22-000008 · edgardoc.xml · derivative · entry 10 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,597 Underlying: Common Stock · 2,553 shares Expires 2022-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options were fully vested on 5/17/13. Read SEC document
January 28, 2022 Filed Feb 1, 2022 18:42 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	850	$0.00 Strike: $20.06	$0.00	Disclosure SEC source: 0001203311-22-000008 · edgardoc.xml · derivative · entry 9 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,150 Underlying: Common Stock · 850 shares Expires 2022-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options were fully vested on 5/17/13. Read SEC document
January 28, 2022 Filed Feb 1, 2022 18:42 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	214	$124.23	$26,585.22	Disclosure SEC source: 0001203311-22-000008 · edgardoc.xml · nonDerivative · entry 8 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $124.13 to $124.29. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
January 28, 2022 Filed Feb 1, 2022 18:42 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	214	$20.06	$4,292.84	Disclosure SEC source: 0001203311-22-000008 · edgardoc.xml · nonDerivative · entry 7 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
January 28, 2022 Filed Feb 1, 2022 18:42 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	883	$123.39	$108,953.37	Disclosure SEC source: 0001203311-22-000008 · edgardoc.xml · nonDerivative · entry 6 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $123.04 to $124.03. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
January 28, 2022 Filed Feb 1, 2022 18:42 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	883	$20.06	$17,712.98	Disclosure SEC source: 0001203311-22-000008 · edgardoc.xml · nonDerivative · entry 5 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
January 28, 2022 Filed Feb 1, 2022 18:42 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	2,553	$122.43	$312,563.79	Disclosure SEC source: 0001203311-22-000008 · edgardoc.xml · nonDerivative · entry 4 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $122.03 to $122.97. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
January 28, 2022 Filed Feb 1, 2022 18:42 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	2,553	$20.06	$51,213.18	Disclosure SEC source: 0001203311-22-000008 · edgardoc.xml · nonDerivative · entry 3 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
January 28, 2022 Filed Feb 1, 2022 18:42 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	850	$121.69	$103,436.50	Disclosure SEC source: 0001203311-22-000008 · edgardoc.xml · nonDerivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $120.99 to $121.96. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
January 28, 2022 Filed Feb 1, 2022 18:42 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	850	$20.06	$17,051.00	Disclosure SEC source: 0001203311-22-000008 · edgardoc.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
January 14, 2022 Filed Jan 19, 2022 18:26 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	4,500	$0.00 Strike: $20.06	$0.00	Disclosure SEC source: 0000899243-22-002477 · doc4.xml · derivative · entry 3 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 4,500 shares Expires 2022-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options were fully vested on 5/17/13. Read SEC document
January 14, 2022 Filed Jan 19, 2022 18:26 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	4,500	$135.24	$608,580.90	Disclosure SEC source: 0000899243-22-002477 · doc4.xml · nonDerivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
January 14, 2022 Filed Jan 19, 2022 18:26 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	4,500	$20.06	$90,270.00	Disclosure SEC source: 0000899243-22-002477 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
June 17, 2021 Filed Jun 21, 2021 20:39 UTC	AERIE PHARMACEUTICALS INC AERI · Entity 122210	GrantStock Option (right to buy) · Derivative	7,800	$0.00 Strike: $16.21	$0.00	Disclosure SEC source: 0001209191-21-042040 · doc4.xml · derivative · entry 3 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2031-06-17 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of June 17, 2021. Read SEC document
June 17, 2021 Filed Jun 21, 2021 20:39 UTC	AERIE PHARMACEUTICALS INC AERI · Entity 122210	GrantCommon Stock	1,750	$0.00	$0.00	Disclosure SEC source: 0001209191-21-042040 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 F1 · shares: Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on June 17, 2022. Read SEC document
May 14, 2021 Filed May 18, 2021 19:31 UTC	Seagen Inc. SGEN · Entity 13956	GrantNon-Qualified Stock Option (right to buy) · Derivative	3,462	$0.00 Strike: $147.50	$0.00	Disclosure SEC source: 0001203311-21-000035 · edgardoc.xml · derivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,462 Underlying: Common Stock · 3,462 shares Expires 2031-05-14 Read SEC document
May 14, 2021 Filed May 18, 2021 19:31 UTC	Seagen Inc. SGEN · Entity 13956	GrantCommon Stock	1,402	$0.00	$0.00	Disclosure SEC source: 0001203311-21-000035 · edgardoc.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 F1 · security: These restricted stock units will be settled in common stock upon vesting. F2 · date: These restricted stock units shall vest in full on May 14, 2022. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
May 05, 2021 Filed May 7, 2021 16:19 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	22,464	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018668 · doc4.xml · derivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 22,464 shares Expires not disclosed F1 · security: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. F2 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F2 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 16:19 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	35,208	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018668 · doc4.xml · derivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 35,208 shares Expires not disclosed F1 · security: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. F2 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F2 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
February 22, 2021 Filed Feb 24, 2021 18:53 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantShare Options · Derivative	22,464	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-008100 · doc4.xml · derivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,464 Underlying: Ordinary Shares · 22,464 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F3 · derivative.exercise_date: These share options will vest in three equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F4 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F3 · derivative.expiration_date: These share options will vest in three equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F4 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document
December 30, 2020 Filed Dec 31, 2020 23:48 UTC	PDL BIOPHARMA, INC. PDLI · Entity 143144	SaleCommon stock	20,000	$2.74	$54,800.00	Disclosure SEC source: 0000882104-20-000217 · wf-form4_160945852572791.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,387 Read SEC document
December 16, 2020 Filed Dec 17, 2020 21:48 UTC	PDL BIOPHARMA, INC. PDLI · Entity 143144	SaleCommon stock	75,000	$2.68	$201,000.00	Disclosure SEC source: 0000882104-20-000209 · wf-form4_160824170002312.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,387 Read SEC document
December 05, 2020 Filed Dec 10, 2020 00:46 UTC	PDL BIOPHARMA, INC. PDLI · Entity 143144	Exercise / conversionStock Option (right to buy) · Derivative	66,050	$1.64 Strike: $1.64	$108,322.00	Disclosure SEC source: 0000882104-20-000202 · wf-form4_160756118399057.xml · derivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 66,050 shares Expires 2029-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 21, 2020, the Company completed the distribution to its stockholders of its shares of common stock in Evofem Biosciences, Inc., which resulted in a $0.58 reduction to the exercise price of the stock option at such time pursuant to the Company's wind-down retention plan. On October 1, 2020, the Company completed the distribution to its stockholders of its shares of common stock in LENSAR, Inc., which resulted in a $0.78 reduction to the exercise price of the stock option at such time pursuant to the Company's wind-down retention plan. Read SEC document
December 05, 2020 Filed Dec 10, 2020 00:46 UTC	PDL BIOPHARMA, INC. PDLI · Entity 143144	Exercise / conversionCommon stock	66,050	$1.64	$108,322.00	Disclosure SEC source: 0000882104-20-000202 · wf-form4_160756118399057.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 03, 2020 Filed Dec 5, 2020 02:17 UTC	PDL BIOPHARMA, INC. PDLI · Entity 143144	SaleCommon stock	75,000	$2.52	$189,000.00	Disclosure SEC source: 0000882104-20-000196 · wf-form4_160713462170052.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,337 Read SEC document
November 23, 2020 Filed Nov 25, 2020 00:25 UTC	PDL BIOPHARMA, INC. PDLI · Entity 143144	SaleCommon stock	50,000	$2.43	$121,500.00	Disclosure SEC source: 0000882104-20-000192 · wf-form4_160626389897559.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,337 Read SEC document
November 19, 2020 Filed Nov 23, 2020 20:11 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	7,871	$0.00 Strike: $19.02	$0.00	Disclosure SEC source: 0001203311-20-000132 · edgardoc.xml · derivative · entry 6 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,871 shares Expires 2021-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options were fully vested on 5/20/12. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
November 19, 2020 Filed Nov 23, 2020 20:11 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	7,129	$0.00 Strike: $19.02	$0.00	Disclosure SEC source: 0001203311-20-000132 · edgardoc.xml · derivative · entry 5 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,871 Underlying: Common Stock · 7,129 shares Expires 2021-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options were fully vested on 5/20/12. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
November 19, 2020 Filed Nov 23, 2020 20:11 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	7,871	$173.25	$1,363,650.75	Disclosure SEC source: 0001203311-20-000132 · edgardoc.xml · nonDerivative · entry 4 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,848 F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $172.75 to $173.74 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
November 19, 2020 Filed Nov 23, 2020 20:11 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	7,871	$19.02	$149,706.42	Disclosure SEC source: 0001203311-20-000132 · edgardoc.xml · nonDerivative · entry 3 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
November 19, 2020 Filed Nov 23, 2020 20:11 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	7,129	$174.20	$1,241,871.80	Disclosure SEC source: 0001203311-20-000132 · edgardoc.xml · nonDerivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,848 F2 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $173.75 to $174.65. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
November 19, 2020 Filed Nov 23, 2020 20:11 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	7,129	$19.02	$135,593.58	Disclosure SEC source: 0001203311-20-000132 · edgardoc.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
November 18, 2020 Filed Nov 19, 2020 22:33 UTC	PDL BIOPHARMA, INC. PDLI · Entity 143144	SaleCommon stock	50,000	$2.39	$119,500.00	Disclosure SEC source: 0000882104-20-000183 · wf-form4_160582519028728.xml · nonDerivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,337 Read SEC document
November 18, 2020 Filed Nov 21, 2020 01:22 UTC	PDL BIOPHARMA, INC. PDLI · Entity 143144	Exercise / conversionStock Option (right to buy) · Derivative	60,000	$1.64 Strike: $1.64	$98,400.00	Disclosure SEC source: 0000882104-20-000188 · wf-form4_160592172411098.xml · derivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,050 Underlying: Common stock · 60,000 shares Expires 2029-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 21, 2020, the Company completed the distribution to its stockholders of its shares of common stock in Evofem Biosciences, Inc., which resulted in a $0.58 reduction to the exercise price of the stock option at such time pursuant to the Company's wind-down retention plan. On October 1, 2020, the Company completed the distribution to its stockholders of its shares of common stock in LENSAR, Inc., which resulted in a $0.78 reduction to the exercise price of the stock option at such time pursuant to the Company's wind-down retention plan. Read SEC document
November 18, 2020 Filed Nov 21, 2020 01:22 UTC	PDL BIOPHARMA, INC. PDLI · Entity 143144	Exercise / conversionCommon stock	60,000	$1.64	$98,400.00	Disclosure SEC source: 0000882104-20-000188 · wf-form4_160592172411098.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.